BMYCelgeneRunning, no new patients
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Myeloproliferative Disorders · Myelofibrosis · Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Anemia
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 313 (final count)
- Started
- Feb 25, 2021
- Main results expected
- May 26, 2025
- Fully finished
- Aug 18, 2032
- Results posted
- Jul 16, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12)
Measured over: From randomization to week 36 (Approximately 36 Weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04717414 · record last updated 2026-07-16 · checked 2026-11-09 15:47 UTC